AMGN stock forecast, quote, news & analysis

Key Takeaways

• Amgen shares rose approximately 8.5% over the 30-day period from mid-June to mid-July 2026, climbing from around $337.60 to $366.29 as of the July 17 close.
• The company delivered a first-quarter 2026 earnings beat in April, posting EPS of $5.15 versus the $4.77 consensus estimate and revenue of $8.62 billion, up 5.8% year-over-year.
• Six key growth drivers — including Repatha, Evenity, Tezspire, rare disease, innovative oncology, and biosimilars — generated 24% aggregate growth in Q1 and now represent nearly 70% of total product sales.
• Pipeline momentum around MariTide, Amgen's GIPR/GLP-1 obesity candidate in the comprehensive MARITIME Phase III program, has drawn significant investor attention, even as the company faces setbacks in other programs.
• Headwinds from Prolia and Xgeva patent expirations are accelerating through 2026, while mixed analyst sentiment reflects the tug-of-war between near-term revenue pressure and long-term pipeline potential.

Current Market Snapshot

Amgen Inc. (AMGN) has exhibited notable resilience in recent weeks, recovering from a mid-June trough near $337 to trade above $366 as of mid-July 2026. The stock's 50-day simple moving average sits at approximately $347.69, while its 200-day moving average hovers around $350.38 — both now below the current share price, suggesting improving near-term technical momentum. With a market capitalization of roughly $197.7 billion and a relatively low beta of 0.41, AMGN has historically traded with less volatility than the broader market. However, 2026 has been described by management as a "springboard year," placing the stock at a pivotal transition point as its legacy blockbusters face intensifying biosimilar competition while next-generation pipeline assets advance toward potential commercialization.

Amgen (AMGN) Business Overview and Competitive Position

Amgen is a global biotechnology pioneer headquartered in Thousand Oaks, California, with roots dating back to 1980. The company discovers, develops, manufactures, and commercializes biologic medicines targeting serious illnesses across oncology, cardiovascular disease, bone health, immunology, neuroscience, and rare diseases. Its commercial portfolio includes well-known therapies such as Repatha (cholesterol), Prolia and Xgeva (bone health), Enbrel and Otezla (inflammation), Tepezza (thyroid eye disease), and Tezspire (asthma). The 2023 acquisition of Horizon Therapeutics significantly expanded Amgen's rare disease footprint and brought Tepezza into the fold. With 17 products now annualizing at over $1 billion in sales, Amgen maintains one of the most diversified revenue bases in biotech, supported by a growing biosimilars business that generated $835 million in Q1 2026 alone. Institutional investors own approximately 76.5% of outstanding shares, reflecting broad confidence in the company's long-term strategy.

Recent Developments Driving AMGN

Several developments in the past 30 days have shaped investor sentiment around Amgen. The company presented fresh Phase 1 data on AMG 133 injection formats for its MariTide obesity program, reinforcing its commitment to competing in the rapidly expanding GLP-1 market alongside players like Eli Lilly and Novo Nordisk. On the analyst front, UBS raised its price target to $420 with a Buy rating, while BMO Capital maintained its Outperform rating and $400 target. Conversely, Bank of America Securities reiterated a Sell rating with a $312 target, citing limited near-term growth visibility. Truist lifted its target to $340, and Cantor Fitzgerald maintained a Neutral $350 rating, noting that while Repatha and Uplizna prescription trends support another potential earnings beat, the broader pipeline offers limited near-term catalysts to extend the stock's recent momentum.

Offsetting the positive sentiment, Amgen halted a late-stage bemarituzumab gastric cancer trial and terminated a key Phase 3 rocatinlimab eczema study — two setbacks that introduced uncertainty into the oncology and immunology pipeline. Additionally, Tavneos faced renewed scrutiny after the New England Journal of Medicine retracted the pivotal ADVOCATE publication, raising questions about data integrity ahead of an FDA hearing process. Despite these challenges, Amgen's Q1 performance and raised full-year 2026 guidance — targeting $37.1 billion to $38.5 billion in revenue and non-GAAP EPS of $21.70 to $23.10 — continue to provide a solid fundamental backdrop.

Trending AI Robots

For traders seeking a data-driven edge in navigating complex stocks like Amgen, Tickeron's Trending AI Robots page offers a curated view into the platform's ecosystem of AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that execute strategies across thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary widely in trading style, holding periods, and performance benchmarks, allowing users to explore approaches ranging from short-term swing trading to longer-term trend-following models. The Trending AI Robots page provides transparency into real-time bot performance, helping traders identify which strategies are currently resonating with market conditions.

2026 Outlook and What Investors Should Watch

Amgen's Q2 2026 earnings report, expected around August 4, will be the next major catalyst for the stock. Analysts are forecasting Q2 EPS of approximately $5.46 to $5.57 on revenue near $9.39 billion. Investors will closely watch prescription trends for Repatha, Evenity, and Uplizna, as well as the pace of sales erosion for Prolia and Xgeva as additional biosimilars enter the market. Updates on MariTide's MARITIME Phase III program — which spans nine studies across obesity, cardiovascular disease, heart failure, and sleep apnea — will remain a central focus, particularly any data readouts or enrollment milestones.

Other key developments include the FDA regulatory process for Tavneos, the Phase III completion of dazodalibep for Sjogren's syndrome expected in the second half of 2026, and the impact of Medicare Part D redesign and Inflation Reduction Act provisions on Enbrel and Otezla pricing. The transition to new CFO Thomas Dittrich in September also warrants attention as the company navigates this capital-intensive period. With 34 analysts covering the stock and a consensus price target of approximately $356.62 — slightly below the current trading level — the market appears to be pricing in a balanced risk-reward profile heading into the second half of 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations